trial

Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia

NCTId NCT00206960
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 56 (actual)
Sponsored by Birte Glenthoj
Primary completion 2010-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
56 (actual)
Study type
Interventional
Allocation
Randomized
Model
Factorial
Masking
None
Start
1998-01
Primary completion
2010-09
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
ZuclopenthixolRisperidone

Sponsors

Birte GlenthojLead Sponsor
University of CopenhagenCollaborator
Glostrup University Hospital, CopenhagenCollaborator
Rigshospitalet, DenmarkCollaborator
Hvidovre University HospitalCollaborator
The Danish Medical Research CouncilCollaborator
Copenhagen Hospital CorporationCollaborator
Janssen-Cilag Farmaceutica Ltda.Collaborator
The Novo Nordic FoundationCollaborator

Investigators

1
Birte Glenthoj, MD, DMSc.Study Director

Sites

6 total
Copenhagen, DenmarkCopenhagen NV, DenmarkCopenhagen NV, DenmarkCopenhagen NV, DenmarkGlostrup Municipality, DenmarkHvidovre, Denmark

Facts & assertions

4 sourced
Enrollment
56
Phase
NA
Primary Completion Date
2010-09
Status
COMPLETED
relationships
The graph out of here
drug
Zuclopenthixol
drug
Risperidone
drug
lead_sponsor
Birte Glenthoj
company
collaborator
University of Copenhagen
company
Glostrup University Hospital, Copenhagen
company
indication
Schizophrenia
indication
Schizophrenia
indication
Cognition Disorders
indication
investigator
Birte Glenthoj, MD, DMSc.
person